Skip to main content
TipRanks
Go Ultimate75% OFF

Ionis Pharmaceuticals (0JDI) Share Price & Analysis

0 Followers

0JDI Stock Chart & Stats

$28.60$1.00(3.63%)
At close: 4:30 PM GMT
$30$40$50$60Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$27.25 - $28.60
52-Week Range
$27.25 - $86.74
Previous Close
$27.60
Volume
N/A
Average Volume (3M)
6,378
Market Cap
$4.84B
Enterprise Value
$7.71B
Total Cash (Recent Filing)
$1.88B
Total Debt (Recent Filing)
$2.15B
Price to Earnings (P/E)
―
Beta
0.71
Next Earnings
Feb 24, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Commercial Revenue Growth

Growing commercial revenue indicates that Ionis is progressing beyond research funding toward a broader product-based earnings model. Continued expansion in sales can improve revenue quality over time, support reinvestment in the pipeline, and increase the company’s participation in future commercial upside.

Positive Late-Stage Pipeline

Positive Phase 3 data for a partnered antisense therapy strengthens confidence in Ionis’s technology platform and development capabilities. If longer-term outcomes and regulatory review remain supportive, the program could generate future milestones, royalties, and a durable presence in kidney disease.

New Approved Products

HIBSAGO approval adds another partnered commercial opportunity and expands Ionis’s exposure to a potentially significant chronic hepatitis B market. The licensing economics allow participation through milestones and royalties while partners provide regulatory and commercial execution capabilities.

Bears Say

Persistent Operating Losses

Deep operating and net losses show that Ionis’s current cost base remains well above the earnings generated by its products, partnerships, and pipeline. Unless revenue growth scales faster than spending, profitability may remain distant and internal funding capacity will stay constrained.

Increasing Cash Burn

Negative operating and free cash flow, combined with a sharp year-over-year increase in burn, raises the company’s ongoing funding requirements. Sustained cash consumption can reduce flexibility to invest across programs, commercial launches, and development opportunities without additional financing.

Slower Launch And Breakeven Delay

The slower TRYNGOLZA launch and delayed cash-flow breakeven indicate that commercialization is taking longer to convert clinical potential into financial returns. Reimbursement friction, limited early repeat prescribing, and program setbacks could prolong losses and increase execution pressure.

Ionis Pharmaceuticals News

0JDI FAQ

What was Ionis Pharmaceuticals’s price range in the past 12 months?
Ionis Pharmaceuticals lowest share price was $27.25 and its highest was $86.74 in the past 12 months.
What is Ionis Pharmaceuticals’s market cap?
Ionis Pharmaceuticals’s market cap is $4.84B.
When is Ionis Pharmaceuticals’s upcoming earnings report date?
Ionis Pharmaceuticals’s next earnings report is estimated for Feb 24, 2027 (not yet confirmed), which is in 100 days.
How were Ionis Pharmaceuticals’s earnings last quarter?
Ionis Pharmaceuticals released its earnings results on Nov 09, 2026. The company reported -$0.66 earnings per share for the quarter, beating the consensus estimate of -$1.23 by $0.57.
Is Ionis Pharmaceuticals overvalued?
According to Wall Street analysts Ionis Pharmaceuticals’s price is currently Undervalued.
Does Ionis Pharmaceuticals pay dividends?
Ionis Pharmaceuticals does not currently pay dividends.
What is Ionis Pharmaceuticals’s EPS estimate?
Ionis Pharmaceuticals’s EPS estimate is -1.35.
How many shares outstanding does Ionis Pharmaceuticals have?
Ionis Pharmaceuticals has 166,545,100 shares outstanding.
What happened to Ionis Pharmaceuticals’s price movement after its last earnings report?
Ionis Pharmaceuticals reported an EPS of -$0.66 in its last earnings report, beating expectations of -$1.23. Following the earnings report the stock price went down -23.205%.
Which hedge fund is a major shareholder of Ionis Pharmaceuticals?
Hedge funds hold Ionis Pharmaceuticals shares: the largest hedge-fund position in Ionis Pharmaceuticals is 93,148,917 shares, and hedge funds increased their holdings by 83.3K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology